TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/17/19 16:19 | 4/15/19 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | M.d | 41 | 20.35 | 0 | 2 | 44 | 7 | D | |||||||||||||||
4/17/19 16:19 | 4/15/19 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | S.d | -105 | 52.66 | 0 | -2 | -24 | 7 | D | |||||||||||||||
3/14/19 16:17 | 3/12/19 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | M.d | 102 | 20.35 | 0 | 5 | 333 | 7 | D | |||||||||||||||
12/4/18 16:19 | 11/30/18 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | M.d | 31 | 20.35 | 0 | 2 | New | 2 | D | |||||||||||||||
10/10/18 16:20 | 10/8/18 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | M.d | 407 | 20.35 | 0 | 20 | 0 | D | ||||||||||||||||
10/10/18 16:20 | 10/8/18 | RGNX | Regenxbio Inc. | Health | BioPrd | Biological Products, (No Diag | Danos Olivier | MD | O | Chief Sc | S.d | -1,276 | 63.80 | 0 | -20 | -100 | 0 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |